Phase 3 Alopecia Areata Trial, Recruiting NCT04594018 Sponsor: EMS Condition: Alopecia Areata
Back to Alopecia Areata

Phase 3 Alopecia Areata Trial, Recruiting

NCT04594018
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to give your voluntary agreement to take part by signing and dating a consent form
  • You are a man aged 18 to 60 years old who has been diagnosed with a specific level of male pattern baldness (grades IIIv to IV on the modified Norwood-Hamilton scale — confirm with trial site if unsure of your grade)
  • You have been using 5% minoxidil for at least 3 months before joining
  • You are willing to keep the same hairstyle, approximate hair length, and hair color throughout the whole trial

Who may not be able to join:

  • You have a known allergy or sensitivity to any of the ingredients used in the trial products
  • You have had a history of alcohol or drug misuse within the last 2 years
  • You have any other skin conditions affecting your scalp, apart from mild dandruff-related skin irritation
  • You have previously had surgery for hair loss or have a shaved scalp
  • You have used shampoos or scalp treatments containing ketoconazole, tar, selenium, threonine, or steroids in the last 2 weeks
  • You have used hair loss medications such as finasteride or dutasteride in the last 12 months
  • You are currently using testosterone replacement therapy or a testosterone-containing gel
  • You have had micro-needling, skin micro-infusion treatments, or similar scalp procedures in the last 3 months
  • You have had radiation treatment to the scalp or chemotherapy in the past year
  • You have any medical condition that can affect hair growth (confirm with trial site)
  • You have a current or recent history of cancer, or have received cancer treatment in the last 5 years

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +551938879851

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
EMS
Registry
ClinicalTrials.gov
Start date
2 February 2023
Est. completion
1 May 2026

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Change from baseline in hair density.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov